Centenary’s discoveries lead to a commercial agreement to create drugs to fix leaking blood vessels
Australian molecular biologists led by researchers at Centenary have made a synthetic compound that appears to allow them to control the leakiness of blood vessels. The work could lead to effective new drug treatments for strokes and tumours. Spinoffs may include an ability to reduce the side-effects of chemotherapy and inflammation.
Their lead drug candidate, known as CD5-2, was developed with the assistance of Mirrx Therapeutics, a privately owned Danish biotechnology company. Today Centenary has signed an agreement to develop this and other potential drugs with Mirrx. The agreement was facilitated by Bio-Link Australia Pty Ltd.